Adial Pharmaceuticals (ADIL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Oct, 2026Executive summary
The 2026 annual meeting was adjourned again on October 15 because Nasdaq approval of the listing application remained pending; it will reconvene October 26, 2026, at 8:30 a.m. ET.
Voting matters and shareholder proposals
Proposals 3, 4, 5 and 6 remain pending, with polls open; no changes were made to the proposals.
Shareholder rights and capital structure
The record date remains August 17, 2026; stockholders who already voted on Proposals 3–6 need not act unless they wish to change their vote.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Adial Pharmaceuticals
- AT177’s 2027 clinical path faces approval risk alongside a 25.1 million-share resale overhang.ADIL
Registration filing - Proposals 3–6 await Nasdaq approval, with voting set to resume Oct. 15.ADILProxy filing
- Shareholders approved new equity plans, increased authorized shares, and key governance proposals.ADILProxy filing
- Investor agreement amendments and preferred stock conversion aim to restore Nasdaq compliance.ADILProxy filing
- Registration enables resale of 25M+ shares post-Azora merger, advancing AT177 for ulcerative colitis.ADILRegistration filing
- Shareholders are asked to approve key merger-related equity issuances, board changes, and new incentive plans.ADILProxy filing
- Q2 net loss reached $52M after Azora deal; cash runway into 2027 but more funding needed.ADILQ2 2026
- Acquisition and financing advance a novel, gut-restricted UC therapy toward clinical proof.ADILInvestor presentation
- Shareholder approval is sought for key proposals enabling Azora merger integration and future growth.ADILProxy filing